Last reviewed · How we verify
Dexamethasone 0.1% ophthalmic suspension
Dexamethasone 0.1% ophthalmic suspension is a Corticosteroid Small molecule drug developed by Azienda USL Reggio Emilia - IRCCS. It is currently FDA-approved for Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, Allergic conjunctivitis, Acute inflammatory conditions of the anterior uveal tract.
Dexamethasone is a potent corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors and inhibiting pro-inflammatory mediator production.
Dexamethasone is a potent corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors and inhibiting pro-inflammatory mediator production. Used for Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, Allergic conjunctivitis, Acute inflammatory conditions of the anterior uveal tract.
At a glance
| Generic name | Dexamethasone 0.1% ophthalmic suspension |
|---|---|
| Sponsor | Azienda USL Reggio Emilia - IRCCS |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing immune cell infiltration and cytokine release. In ophthalmic suspension form, it penetrates ocular tissues to provide local anti-inflammatory effects while minimizing systemic exposure. This mechanism makes it effective for treating various inflammatory and allergic eye conditions.
Approved indications
- Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe
- Allergic conjunctivitis
- Acute inflammatory conditions of the anterior uveal tract
- Corneal injury from chemical, radiation, or thermal burns
- Post-operative inflammation following ocular surgery
Common side effects
- Elevated intraocular pressure
- Posterior subcapsular cataract formation
- Local irritation or discomfort
- Blurred vision
- Secondary ocular infection
Key clinical trials
- The OPTIMISE Study (PHASE4)
- Bromfenac Versus Dexamethasone After Cataract Surgery (PHASE4)
- Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (PHASE4)
- Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents (PHASE4)
- FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis (PHASE2)
- FST-100 in the Treatment of Acute Adenoviral Conjunctivitis (PHASE2)
- Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo (PHASE3)
- Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone 0.1% ophthalmic suspension CI brief — competitive landscape report
- Dexamethasone 0.1% ophthalmic suspension updates RSS · CI watch RSS
- Azienda USL Reggio Emilia - IRCCS portfolio CI
Frequently asked questions about Dexamethasone 0.1% ophthalmic suspension
What is Dexamethasone 0.1% ophthalmic suspension?
How does Dexamethasone 0.1% ophthalmic suspension work?
What is Dexamethasone 0.1% ophthalmic suspension used for?
Who makes Dexamethasone 0.1% ophthalmic suspension?
What drug class is Dexamethasone 0.1% ophthalmic suspension in?
What development phase is Dexamethasone 0.1% ophthalmic suspension in?
What are the side effects of Dexamethasone 0.1% ophthalmic suspension?
What does Dexamethasone 0.1% ophthalmic suspension target?
Related
- Drug class: All Corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: Azienda USL Reggio Emilia - IRCCS — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe
- Indication: Drugs for Allergic conjunctivitis
- Indication: Drugs for Acute inflammatory conditions of the anterior uveal tract
- Compare: Dexamethasone 0.1% ophthalmic suspension vs similar drugs
- Pricing: Dexamethasone 0.1% ophthalmic suspension cost, discount & access